文献速递白血病

可测量残留病作为急性髓系白血病生物标志物的理论与实践考量

Measurable residual disease as a biomarker in acute myeloid leukemia: theoretical and practical considerations.
PubMed 文献 · Leukemia · 2021-03-23

本文综述了可测量残留病(MRD)在急性髓系白血病(AML)中的检测方法、预后价值及临床应用。MRD与不良结局强相关,可用于指导缓解后治疗和监测复发,但作为预测性生物标志物的证据有限。MRD作为替代终点加速药物开发需前瞻性试验验证。

要点

  • MRD与AML患者不良结局强相关,已用于常规护理和临床试验。
  • MRD结果可指导部分患者缓解后治疗选择,但预测性证据有限。
  • MRD从不可测转为可测或水平上升与复发相关,可用于监测。

核心结论

  • MRD在AML中的预后价值已确立,但作为预测性生物标志物和替代终点的证据仍需前瞻性试验验证。

研究设计与样本

  • 综述,讨论基于免疫表型或分子异常检测MRD的方法及其在AML中的应用。

主要发现

  • MRD与不良患者结局强相关,促使将MRD作为生物标志物用于常规护理和临床试验。
  • 回顾性研究表明MRD从不可测转为可测或随时间增加与明显疾病复发相关。
  • 解读连续MRD数据复杂,最佳检测时机、频率及定义复发的阈值尚不明确。
  • 在MRD检测时干预而非明显复发时干预是否改善结局尚不清楚。

临床怎么用

  • MRD检测可用于部分AML患者缓解后治疗选择及复发早期监测。
  • 连续MRD监测需考虑检测时机、频率及阈值等未解决问题。

局限性

  • 支持MRD作为预测性生物标志物的证据仍有限。
  • 缺乏前瞻性临床试验数据确认治疗对MRD的影响直接与临床结局相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Several methodologies that rely on the detection of immunophenotypic or molecular abnormalities of the neoplastic cells are now available to quantify measurable ("minimal") residual disease (MRD) in acute myeloid leukemia (AML). Although the perfect MRD test does not (yet) exist, the strong association between MRD and adverse patient outcomes has provided the impetus to use measures of MRD as biomarker in the routine care of AML patients and during clinical trials. MRD test results may inform the selection of postremission therapy in some patients but evidence supporting the use of MRD as predictive biomarker is still limited. Several retrospective studies have shown that conversion from undetectable to detectable MRD or increasing MRD over time is associated with overt disease recurrence, and MRD testing may therefore be valuable as a monitoring biomarker for early detection of relapse. Interpreting serial MRD data is complex, with open questions regarding the optimal timing and frequency of testing, as well as the identification of test-specific thresholds to define relapse. Importantly, it is unknown whether intervening at the time of MRD detection, rather than at overt disease recurrence, improves outcomes. Finally, using MRD as a surrogate efficacy-response biomarker to accelerate drug development/approval has already been accepted by regulatory authorities in other diseases and is of great interest as a potential strategy in AML. While the prognostic value of MRD in AML is well established, data from prospective clinical trials confirming that treatment effects on MRD directly relate to clinical outcomes are needed to further establish the role of MRD as a surrogate endpoint in AML.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Walter RB, Ofran Y, Wierzbowska A, et al. Measurable residual disease as a biomarker in acute myeloid leukemia: theoretical and practical considerations. Leukemia. 2021. PMID: 33758317. doi:10.1038/s41375-021-01230-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。